{
  "url": "https://finance.yahoo.com/news/anagenics-full-2025-earnings-au-213718666.html",
  "authorsByline": "Simply Wall St",
  "articleId": "20baff1a015a41369217ad148bdfa67e",
  "source": {
    "domain": "finance.yahoo.com",
    "location": {
      "country": "us",
      "state": "CA",
      "county": "Santa Clara County",
      "city": "Sunnyvale",
      "coordinates": {
        "lat": 37.3688301,
        "lon": -122.036349
      }
    }
  },
  "imageUrl": "https://media.zenfs.com/en/simply_wall_st__316/78a8c60a6283aea0450523395306d38c",
  "country": "us",
  "language": "en",
  "pubDate": "2025-08-29T21:37:18+00:00",
  "addDate": "2025-08-29T21:52:25.558446+00:00",
  "refreshDate": "2025-08-29T21:52:25.558448+00:00",
  "score": 1.0,
  "title": "Anagenics Full Year 2025 Earnings: AU$0.003 loss per share (vs AU$0.018 loss in FY 2024)",
  "description": "Anagenics ( ASX:AN1 ) Full Year 2025 Results Key Financial Results Revenue: AU$5.12m (down 53% from FY 2024). Net loss...",
  "content": "\u2022 AU$0.003 loss per share (improved from AU$0.018 loss in FY 2024).\n\nAI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early.\n\nAll figures shown in the chart above are for the trailing 12 month (TTM) period\n\nAnagenics shares are down 17% from a week ago.\n\nBe aware that Anagenics is showing 5 warning signs in our investment analysis and 4 of those are potentially serious...\n\nHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.\n\n\n\nThis article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.",
  "medium": "Article",
  "links": [
    "https://investor-research.typeform.com/to/wvg6MFri#feedback_token=NDAyNTc4ODo2MTUzMjIxNTYxM2Y3ZWVi&company=Anagenics&blueprintid=4025788",
    "https://simplywall.st/company/id/BD8BAD47-B909-4D6E-8A0D-907166EE4709/past?blueprint=4025788&amp;utm_medium=finance_user&amp;utm_campaign=infographic&amp;utm_source=yahoo",
    "https://simplywall.st/discover/investing-ideas/434426/us-transformative-artificial-intelligence-ai-healthcare-stocks/global?blueprint=4025788&utm_medium=finance_user&utm_campaign=investing-ideas&utm_source=yahoo&utm_content=ai-healthcare",
    "https://au.finance.yahoo.com/quote/AN1.AX",
    "https://simplywall.st/company/id/BD8BAD47-B909-4D6E-8A0D-907166EE4709?blueprint=4025788&utm_medium=finance_user&utm_campaign=conclusion&utm_source=yahoo"
  ],
  "labels": [
    {
      "name": "Roundup"
    }
  ],
  "claim": "",
  "verdict": "",
  "keywords": [
    {
      "name": "Anagenics shares",
      "weight": 0.09549835
    },
    {
      "name": "Simply Wall St",
      "weight": 0.086306594
    },
    {
      "name": "Anagenics Full Year",
      "weight": 0.08399273
    },
    {
      "name": "historical data",
      "weight": 0.07926228
    },
    {
      "name": "fundamental data",
      "weight": 0.07361577
    },
    {
      "name": "Anagenics",
      "weight": 0.073468104
    },
    {
      "name": "analyst forecasts",
      "weight": 0.070612036
    },
    {
      "name": "early diagnostics",
      "weight": 0.070541464
    },
    {
      "name": "share",
      "weight": 0.06973066
    },
    {
      "name": "financial advice",
      "weight": 0.06890468
    }
  ],
  "topics": [
    {
      "name": "Markets"
    }
  ],
  "categories": [
    {
      "name": "Finance"
    }
  ],
  "taxonomies": [
    {
      "name": "/News/Business News/Financial Markets News",
      "score": 0.97998046875
    },
    {
      "name": "/News/Business News/Company News",
      "score": 0.9677734375
    },
    {
      "name": "/Finance/Investing/Stocks & Bonds",
      "score": 0.95947265625
    },
    {
      "name": "/Business & Industrial/Pharmaceuticals & Biotech",
      "score": 0.919921875
    }
  ],
  "sentiment": {
    "positive": 0.034917522,
    "negative": 0.80251807,
    "neutral": 0.16256446
  },
  "summary": "Anagenics shares are down 17% from a week ago. The company is showing five warning signs in our investment analysis, including a potential increase in its loss rate of AU$0.003 per share for the full year of 2025. These stocks are under $10bn in marketcap and there is still time to invest in them early. The article is based on historical data and analyst forecasts, but does not represent a recommendation for purchase or modification.",
  "shortSummary": "Anagenics reported a loss of AU$0.003 per share, prompting concerns about potential insider trading and potential market closures.",
  "translation": "",
  "translatedTitle": "",
  "translatedDescription": "",
  "translatedSummary": "",
  "reprint": false,
  "reprintGroupId": "71ff2b54b2e94dd6892e48bfb398f84b",
  "places": [],
  "scraped_sources": [
    {
      "url": "https://simplywall.st/discover/investing-ideas/434426/us-transformative-artificial-intelligence-ai-healthcare-stocks/global?blueprint=4025788&utm_medium=finance_user&utm_campaign=investing-ideas&utm_source=yahoo&utm_content=ai-healthcare",
      "text": "Results\n27\nArtificial intelligence (AI) is set to transform healthcare by enhancing diagnostics, personalizing medicine, boosting operational efficiency, expanding remote care, and accelerating research. AI outperforms humans in detecting diseases like cancer from scans, tailors treatments using genetic and lifestyle data, and streamlines hospital workflows with tools like predictive analytics and automated transcription. It powers telemedicine, monitors chronic conditions in real-time, and speeds up drug discovery by analyzing vast datasets for insights into complex diseases. Despite challenges like data privacy, bias, and integration costs, AI\u2019s ability to improve accuracy, access, and affordability could save billions and extend lives, marking a seismic shift in healthcare delivery and outcomes.\n27 companies\nCosmo Pharmaceuticals\nMarket Cap: US$994.6m\nFocuses on the development and commercialization products for gastroenterology, dermatology, and healthtech worldwide.\nCMOP.F\nUS$75.00\n7D\n0%\n1Y\n-21.1%\nGubra\nMarket Cap: US$5.8b\nA biotech company, focuses on the pre-clinical contract research and peptide-based drug discovery within metabolic and fibrotic diseases in Europe, North America, and internationally.\nGUBR.F\nUS$60.15\n7D\n0%\n1Y\nn/a\nEvaxion\nMarket Cap: US$19.2m\nA clinical-stage biotech company, develops artificial intelligence-powered immunology vaccines.\nEVAX\nUS$2.75\n7D\n-15.4%\n1Y\n-82.0%\nImmunoPrecise Antibodies\nMarket Cap: US$114.9m\nOperates as an AI-driven biotherapeutic research, technology, and scientifically robust life science company.\nIPA\nUS$2.37\n7D\n-25.9%\n1Y\n213.9%\nCareCloud\nMarket Cap: US$160.0m\nA healthcare information technology (IT) company, provides technology-enabled business solutions, Software-as-a-Service offerings, and related business services to healthcare providers and hospitals primarily in the United States.\nCCLD\nUS$3.84\n7D\n35.7%\n1Y\n43.8%\nGeneDx Holdings\nMarket Cap: US$3.7b\nA genomics company, provides genetic testing services.\nWGS\nUS$129.49\n7D\n0.6%\n1Y\n305.4%\nSpectral AI\nMarket Cap: US$53.2m\nAn artificial intelligence (AI) company, focuses on predictive medical diagnostics in the United States.\nMDAI\nUS$1.93\n7D\n-7.7%\n1Y\n35.0%\nWELL Health Technologies\nMarket Cap: US$1.2b\nOperates as a practitioner-focused digital healthcare company in Canada, the United States, and internationally.\nWHTC.F\nUS$3.48\n7D\n-2.2%\n1Y\n3.6%\nRevenio Group Oyj\nMarket Cap: US$639.8m\nProvides ophthalmological devices and software solutions for the diagnosis of glaucoma, macular degeneration, and diabetic retinopathy in Finland, the United States, and internationally.\nREVX.F\nUS$31.47\n7D\n0%\n1Y\nn/a\nRadNet\nMarket Cap: US$5.5b\nProvides outpatient diagnostic imaging services in the United States and internationally.\nRDNT\nUS$71.79\n7D\n4.6%\n1Y\n11.0%\nSimulations Plus\nMarket Cap: US$286.2m\nDevelops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide.\nSLP\nUS$14.17\n7D\n-2.7%\n1Y\n-60.9%\nRakovina Therapeutics\nMarket Cap: US$10.6m\nA biopharmaceutical research company, engages in the research and development of cancer treatments based on novel series of small-molecule DNA-damage response targets.\nRKVT.F\nUS$0.30\n7D\n-18.6%\n1Y\nn/a\nNano-X Imaging\nMarket Cap: US$251.9m\nDevelops a commercial-grade tomographic imaging device with a digital X-ray source.\nNNOX\nUS$3.88\n7D\n-3.2%\n1Y\n-38.2%\nHeartSciences\nMarket Cap: US$12.6m\nA medical technology company, focuses on applying AI-based technology to an ECG to expand and improve clinical usefulness.\nHSCS\nUS$3.41\n7D\n-6.6%\n1Y\n0.3%\nPerimeter Medical Imaging AI\nMarket Cap: US$23.8m\nA medical technology company, provides advanced imaging solutions to address unmet medical needs.\nPYNK.F\nUS$0.16\n7D\n-8.5%\n1Y\n-31.6%\nGuardant Health\nMarket Cap: US$8.0b\nA precision oncology company, provides blood and tissue tests, and data sets in the United States and internationally.\nGH\nUS$67.42\n7D\n9.8%\n1Y\n163.6%\nCeriBell\nMarket Cap: US$438.9m\nOperates as a medical technology company focuses on transforming the diagnosis and management of patients with serious neurological conditions in the United States.\nCBLL\nUS$11.83\n7D\n-1.9%\n1Y\nn/a\nOmniAb\nMarket Cap: US$201.2m\nA biotechnology company, licenses discovery research technology to pharmaceutical and biotech companies, and academic institutions to enable the discovery of therapeutics in the United States, Europe, Japan, China, and Canada.\nOABI\nUS$1.60\n7D\n-13.5%\n1Y\n-61.8%\nBioXcel Therapeutics\nMarket Cap: US$59.7m\nTogether with its subsidiary, OnkosXcel Therapeutics LLC, operates as a biopharmaceutical company that utilizes artificial intelligence approaches to develop medicines in neuroscience and immuno-oncology in the United States.\nBTAI\nUS$4.05\n7D\n-18.7%\n1Y\n-58.8%\nXtalPi Holdings\nMarket Cap: US$41.4b\nAn investment holding company, engages in the provision of robotics and drug discovery solutions in Mainland China, the United States, and internationally.\nQNTP.F\nUS$1.40\n7D\n16.7%\n1Y\nn/a\nNeuroOne Medical Technologies\nMarket Cap: US$36.9m\nA medical technology company, provides solutions for continuous electroencephalogram (cEEG) and stereoelectrocencephalography (sEEG) recording in the United States.\nNMTC\nUS$0.76\n7D\n-2.6%\n1Y\n-4.0%\nLantheus Holdings\nMarket Cap: US$3.9b\nDevelops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in diagnosis and treatment of heart, cancer, and other diseases worldwide.\nLNTH\nUS$55.50\n7D\n-6.2%\n1Y\n-47.0%\nAcarix\nMarket Cap: US$314.5m\nA medical device company, develops solutions for rapid AI-based coronary artery disease rule-out.\nACIX.F\nUS$0.035\n7D\n-4.8%\n1Y\n9.0%\nAbsci\nMarket Cap: US$369.3m\nOperates as a data-first generative artificial intelligence (AI) drug creation company in the United States.\nABSI\nUS$2.39\n7D\n-9.1%\n1Y\n-45.7%\nHealwell AI\nMarket Cap: US$359.4m\nA healthcare artificial intelligence company, develops and commercializes clinical decision support systems in Canada, New Zealand, Australia, and the United Kingdom.\nHWAI.F\nUS$0.95\n7D\n-4.1%\n1Y\n-31.7%\nPersonalis\nMarket Cap: US$423.9m\nDevelops, markets, and sells advanced cancer genomic tests and services in the United States and internationally.\nPSNL\nUS$4.78\n7D\n2.6%\n1Y\n-17.6%\nVeradigm\nMarket Cap: US$837.3m\nA healthcare technology company, provides information technology solutions to healthcare providers, payers, and biopharma markets in the United States and internationally.\nMDRX\nUS$4.90\n7D\n1.0%\n1Y\n-50.8%"
    },
    {
      "url": "https://simplywall.st/company/id/BD8BAD47-B909-4D6E-8A0D-907166EE4709/past?blueprint=4025788&amp;utm_medium=finance_user&amp;utm_campaign=infographic&amp;utm_source=yahoo",
      "text": "Anagenics Past Earnings Performance\nPast criteria checks 0/6\nAnagenics's earnings have been declining at an average annual rate of -2.9%, while the Personal Products industry saw earnings growing at 8.4% annually. Revenues have been growing at an average rate of 4.6% per year.\nKey information\n-2.95%\nEarnings growth rate\n36.51%\nEPS growth rate\n| Personal Products Industry Growth | -25.22% |\n| Revenue growth rate | 4.64% |\n| Return on equity | -67.65% |\n| Net Margin | -24.14% |\n| Last Earnings Update | 30 Jun 2025 |\nRecent past performance updates\nRecent updates\nRevenue & Expenses Breakdown\nHow Anagenics makes and spends money. Based on latest reported earnings, on an LTM basis.\nEarnings and Revenue History\n| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |\n|---|---|---|---|---|\n| 30 Jun 25 | 5 | -1 | 3 | 0 |\n| 31 Mar 25 | 6 | -4 | 4 | 0 |\n| 31 Dec 24 | 7 | -6 | 6 | 0 |\n| 30 Sep 24 | 9 | -7 | 6 | 0 |\n| 30 Jun 24 | 11 | -7 | 7 | 0 |\n| 31 Mar 24 | 10 | -5 | 7 | 0 |\n| 31 Dec 23 | 10 | -3 | 7 | 0 |\n| 30 Sep 23 | 10 | -2 | 6 | 0 |\n| 30 Jun 23 | 9 | -2 | 6 | 0 |\n| 31 Mar 23 | 9 | -1 | 6 | 0 |\n| 31 Dec 22 | 9 | -1 | 7 | 0 |\n| 30 Sep 22 | 8 | -1 | 7 | 0 |\n| 30 Jun 22 | 7 | -2 | 7 | 0 |\n| 31 Dec 21 | 6 | -3 | 6 | 0 |\n| 30 Sep 21 | 6 | -3 | 6 | 0 |\n| 30 Jun 21 | 6 | -4 | 6 | 0 |\n| 31 Dec 20 | 6 | -5 | 7 | 0 |\n| 30 Sep 20 | 7 | -5 | 8 | 0 |\n| 30 Jun 20 | 7 | -4 | 8 | 0 |\n| 31 Mar 20 | 8 | -4 | 8 | 1 |\n| 31 Dec 19 | 8 | -4 | 8 | 1 |\n| 30 Sep 19 | 7 | -5 | 9 | 1 |\n| 30 Jun 19 | 7 | -6 | 10 | 1 |\n| 31 Mar 19 | 7 | -6 | 9 | 1 |\n| 31 Dec 18 | 6 | -6 | 8 | 1 |\n| 30 Sep 18 | 6 | -5 | 7 | 1 |\n| 30 Jun 18 | 6 | -4 | 6 | 1 |\n| 31 Mar 18 | 6 | -4 | 6 | 1 |\n| 31 Dec 17 | 6 | -4 | 6 | 1 |\n| 30 Sep 17 | 5 | -4 | 6 | 1 |\n| 30 Jun 17 | 5 | -4 | 6 | 1 |\n| 31 Mar 17 | 4 | -4 | 6 | 0 |\n| 31 Dec 16 | 4 | -3 | 6 | 0 |\n| 30 Sep 16 | 4 | -3 | 6 | 0 |\n| 30 Jun 16 | 3 | -3 | 6 | 0 |\n| 31 Mar 16 | 3 | -4 | 5 | 1 |\n| 31 Dec 15 | 3 | -4 | 5 | 1 |\n| 30 Sep 15 | 2 | -4 | 4 | 1 |\n| 30 Jun 15 | 2 | -3 | 4 | 1 |\n| 31 Mar 15 | 2 | -3 | 4 | 1 |\n| 31 Dec 14 | 1 | -3 | 3 | 1 |\n| 30 Sep 14 | 2 | -2 | 3 | 1 |\nQuality Earnings: AN1 is currently unprofitable.\nGrowing Profit Margin: AN1 is currently unprofitable.\nFree Cash Flow vs Earnings Analysis\nPast Earnings Growth Analysis\nEarnings Trend: AN1 is unprofitable, and losses have increased over the past 5 years at a rate of 2.9% per year.\nAccelerating Growth: Unable to compare AN1's earnings growth over the past year to its 5-year average as it is currently unprofitable\nEarnings vs Industry: AN1 is unprofitable, making it difficult to compare its past year earnings growth to the Personal Products industry (2%).\nReturn on Equity\nHigh ROE: AN1 has a negative Return on Equity (-67.65%), as it is currently unprofitable.\nReturn on Assets\nReturn on Capital Employed\nDiscover strong past performing companies\nCompany Analysis and Financial Data Status\n| Data | Last Updated (UTC time) |\n|---|---|\n| Company Analysis | 2025/08/29 22:38 |\n| End of Day Share Price | 2025/08/29 00:00 |\n| Earnings | 2025/06/30 |\n| Annual Earnings | 2025/06/30 |\nData Sources\nThe data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.\n| Package | Data | Timeframe | Example US Source * |\n|---|---|---|---|\n| Company Financials | 10 years |\n| |\n| Analyst Consensus Estimates | +3 years |\n|\n|\n| Market Prices | 30 years |\n| |\n| Ownership | 10 years |\n| |\n| Management | 10 years |\n| |\n| Key Developments | 10 years |\n|\n* Example for US securities, for non-US equivalent regulatory forms and sources are used.\nUnless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.\nAnalysis Model and Snowflake\nDetails of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.\nLearn about the world class team who designed and built the Simply Wall St analysis model.\nIndustry and Sector Metrics\nOur industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.\nAnalyst Sources\nAnagenics Limited is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.\n| Analyst | Institution |\n|---|---|\n| Stuart Roberts | Pitt Street Research Pty Ltd. |"
    },
    {
      "url": "https://simplywall.st/company/id/BD8BAD47-B909-4D6E-8A0D-907166EE4709?blueprint=4025788&utm_medium=finance_user&utm_campaign=conclusion&utm_source=yahoo",
      "text": "Anagenics (AN1) Stock Overview\nEngages in the health wellness and beauty business. More details\n| Snowflake Score | |\n|---|---|\n| Valuation | 2/6 |\n| Future Growth | 0/6 |\n| Past Performance | 0/6 |\n| Financial Health | 2/6 |\n| Dividends | 0/6 |\nAN1 Community Fair Values\nSee what others think this stock is worth. Follow their fair value or set your own to get alerts.\nAnagenics Limited Competitors\nPrice History & Performance\n| Historical stock prices | |\n|---|---|\n| Current Share Price | AU$0.005 |\n| 52 Week High | AU$0.009 |\n| 52 Week Low | AU$0.004 |\n| Beta | -0.074 |\n| 1 Month Change | 0% |\n| 3 Month Change | -16.67% |\n| 1 Year Change | -37.50% |\n| 3 Year Change | -84.38% |\n| 5 Year Change | -95.45% |\n| Change since IPO | -99.87% |\nRecent News & Updates\nRecent updates\nShareholder Returns\n| AN1 | AU Personal Products | AU Market | |\n|---|---|---|---|\n| 7D | -16.7% | -2.4% | -0.3% |\n| 1Y | -37.5% | 20.7% | 11.0% |\nReturn vs Industry: AN1 underperformed the Australian Personal Products industry which returned 20.7% over the past year.\nReturn vs Market: AN1 underperformed the Australian Market which returned 11% over the past year.\nPrice Volatility\n| AN1 volatility | |\n|---|---|\n| AN1 Average Weekly Movement | 34.7% |\n| Personal Products Industry Average Movement | 12.5% |\n| Market Average Movement | 8.9% |\n| 10% most volatile stocks in AU Market | 19.3% |\n| 10% least volatile stocks in AU Market | 3.5% |\nStable Share Price: AN1's share price has been volatile over the past 3 months compared to the Australian market.\nVolatility Over Time: Insufficient data to determine AN1's volatility change over the past year.\nAbout the Company\n| Founded | Employees | CEO | Website |\n|---|---|---|---|\n| 2004 | n/a | n/a | anagenics.com |\nAnagenics Limited engages in the health wellness and beauty business. The company develops, manufactures, and markets anti-ageing hair care products under the \u00e9volis brand; and skin, hair, and body care products under the Uspa brand name. It also imports and distributes skin care and wellbeing products to spas, clinics, salons, retail stores, and online in Australia, New Zealand, and the Pacific Islands.\nAnagenics Limited Fundamentals Summary\n| AN1 fundamental statistics | |\n|---|---|\n| Market cap | AU$2.48m |\n| Earnings (TTM) | -AU$1.24m |\n| Revenue (TTM) | AU$5.12m |\nIs AN1 overvalued?\nSee Fair Value and valuation analysisEarnings & Revenue\n| AN1 income statement (TTM) | |\n|---|---|\n| Revenue | AU$5.12m |\n| Cost of Revenue | AU$2.71m |\n| Gross Profit | AU$2.41m |\n| Other Expenses | AU$3.65m |\n| Earnings | -AU$1.24m |\nLast Reported Earnings\nJun 30, 2025\nNext Earnings Date\nn/a\n| Earnings per share (EPS) | -0.0025 |\n| Gross Margin | 47.08% |\n| Net Profit Margin | -24.14% |\n| Debt/Equity Ratio | 29.6% |\nHow did AN1 perform over the long term?\nSee historical performance and comparisonCompany Analysis and Financial Data Status\n| Data | Last Updated (UTC time) |\n|---|---|\n| Company Analysis | 2025/08/29 22:38 |\n| End of Day Share Price | 2025/08/29 00:00 |\n| Earnings | 2025/06/30 |\n| Annual Earnings | 2025/06/30 |\nData Sources\nThe data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.\n| Package | Data | Timeframe | Example US Source * |\n|---|---|---|---|\n| Company Financials | 10 years |\n| |\n| Analyst Consensus Estimates | +3 years |\n|\n|\n| Market Prices | 30 years |\n| |\n| Ownership | 10 years |\n| |\n| Management | 10 years |\n| |\n| Key Developments | 10 years |\n|\n* Example for US securities, for non-US equivalent regulatory forms and sources are used.\nUnless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.\nAnalysis Model and Snowflake\nDetails of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.\nLearn about the world class team who designed and built the Simply Wall St analysis model.\nIndustry and Sector Metrics\nOur industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.\nAnalyst Sources\nAnagenics Limited is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.\n| Analyst | Institution |\n|---|---|\n| Stuart Roberts | Pitt Street Research Pty Ltd. |"
    }
  ],
  "argos_summary": "AI is poised to transform healthcare, with 27 companies\u2014most under $10bn market cap\u2014leveraging AI for diagnostics, drug discovery, and operational efficiency. The report highlights significant gains for some firms while noting risks, such as Anagenics\u2019 declining earnings and warning signs. Overall, AI\u2019s potential to improve accuracy, access, and affordability could save billions and extend lives, marking a seismic shift in healthcare delivery.",
  "argos_id": "BSFAKOETF"
}